金石亚药(300434) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥196,392,938.35, representing a 33.59% increase compared to the same period last year[3] - The net profit attributable to shareholders was ¥6,812,854.64, marking a turnaround from a loss to profit[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥5,776,722.74, also indicating a turnaround[3] - The company reported a 51.14% increase in total revenue for the year-to-date, amounting to ¥731,928,047.69, driven by higher sales volumes[10] - Total operating revenue for Q3 2021 reached ¥731,928,047.69, a significant increase of 51.1% compared to ¥484,265,292.11 in the same period last year[24] - Net profit for Q3 2021 was ¥79,843,438.30, a turnaround from a net loss of ¥94,845,203.09 in Q3 2020[25] - The company's basic earnings per share for Q3 2021 was ¥0.02, reflecting a recovery from previous losses[3] - The company reported a basic earnings per share of ¥0.2, compared to a loss per share of ¥0.24 in the previous year[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,603,391,033.45, an increase of 4.38% from the end of the previous year[3] - Total assets increased to ¥2,603,391,033.45, up from ¥2,494,196,271.25 at the end of the previous year[22] - The total liabilities decreased slightly to ¥427,642,186.18 from ¥435,227,944.52 year-over-year[22] - The total liabilities of the company stood at CNY 435.23 million, unchanged from the previous year[34] - The total assets of the company remained at CNY 2.49 billion, consistent with the previous year[34] - The company's equity attributable to shareholders was CNY 2.02 billion, unchanged from the previous year[34] Cash Flow - The operating cash flow for the year-to-date was ¥104,906,427.50, up 44.14% year-on-year[10] - The company’s cash flow from operating activities was ¥708,262,780.15, compared to ¥544,640,486.62 in the previous period[28] - The net cash flow from operating activities for Q3 2021 was CNY 104.91 million, an increase of 44.0% compared to CNY 72.78 million in Q3 2020[29] - Total cash inflow from operating activities reached CNY 788.89 million, up from CNY 617.32 million in the same period last year, reflecting a growth of 27.7%[29] - Cash outflow from operating activities was CNY 683.98 million, compared to CNY 544.54 million in Q3 2020, representing an increase of 25.6%[29] - The net cash flow from investing activities was negative CNY 227.56 million, worsening from a negative CNY 10.64 million in Q3 2020[30] - Cash and cash equivalents at the end of Q3 2021 totaled CNY 241.92 million, down from CNY 375.08 million at the end of Q3 2020, a decrease of 35.4%[30] - The company reported a total cash outflow from financing activities of CNY 46.15 million, compared to CNY 32.60 million in Q3 2020, indicating an increase of 41.6%[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 10,892[12] - The largest shareholder, Gao Yaping, holds 25.11% of the shares, totaling 100,878,929 shares[12] - The total number of restricted shares at the end of the period is 13,645,440, with an increase of 3,343,860 during the reporting period[15] - The company transitioned to having no controlling shareholder after the share transfer agreement completed on September 17, 2021[16] Expenses and Investments - Research and development expenses increased by 53.93% to ¥27,762,817.13 due to higher labor and material costs[10] - Research and development expenses for the quarter were ¥27,762,817.13, an increase from ¥18,035,832.62 in the same quarter last year[24] - The company's investment income showed a significant decline, with a loss of ¥6,042,454.57, a 420.08% increase in losses compared to the previous year[10] - The company experienced a 2039.32% increase in cash outflows from investment activities, totaling -¥227,557,975.51, primarily due to substantial payments for equity transfers[10] Other Financial Metrics - The company's goodwill increased from ¥97,120,057.82 to ¥199,933,532.58, a rise of about 105.5%[20] - Long-term equity investments increased from ¥82,101,828.41 to ¥138,598,609.10, reflecting a growth of approximately 68.9%[20] - Deferred income tax assets rose to ¥10,609,103.00 from ¥6,051,345.91 year-over-year[21] - The company executed a new leasing standard starting in 2021, which required adjustments to the financial statements[31] - The third quarter report of Sichuan Jinshi Asia Pharmaceutical Co., Ltd. is unaudited[36]